BCOP Updates 2024: Bundle

UAN#: 0465-0000-24-085-H01-P

Author: Sarah Chehab, PharmD, BCOP

Learning Objectives

1. Review the evolution in the treatment landscape for metastatic cholangiocarcinoma, including current first-line therapy recommendations
2. Analyze current literature relating to treatment options for patients with metastatic cholangiocarcinoma
3. Summarize the role of targeted therapies in the treatment landscape of cholangiocarcinoma
4. Examine toxicities of targeted therapies used in the treatment of metastatic cholangiocarcinoma

UAN#: 0465-0000-24-086-H01-P

Authors:  Kelsea Seago, PharmD, BCOP

Spencer K. Yingling, PharmD, BCOP*

*All participation and contribution to this presentation regarding clinical content occurred during time in clinical practice prior to employment with Bristol Myers Squibb.

Learning Objectives: 

1. Discuss FDA-approved indications and recent guideline updates for CAR T-cell therapies
2. Recognize potentially practice-changing literature associated with currently available CAR T-cell therapy products
3. Describe novel CAR T-cell therapies under clinical trial investigation
4. Summarize appropriate implementation policies and procedures for CAR T-cell therapy administration in an outpatient setting
5. Compare and contrast toxicity monitoring and management strategies for CAR T-cell therapy between inpatient and outpatient settings
6. Outline the expanding role of the oncology pharmacist in the treatment of cancers utilizing CAR T-cell therapies

UAN#: 0465-0000-24-087-H01-P

Author: Michael Williams, PharmD, BCOP

Learning Objectives:

1. Identify the mechanistic target and indication for each FDA-approved BsAb therapy among hematologic malignancies.
2. Recall package insert recommendations to aid decision-making for the appropriate administration setting.
3. Provide supportive care  recommendations for the prevention and management of BsAb-related adverse events in multiple myeloma.
4. Apply knowledge of CRS and ICANS to compare risks between BsAbs and CAR T-cell therapy.

UAN#: 0465-0000-24-088-H01-P

Author: Andy Maldonado, PharmD, BCOP

Learning Objectives:

1. Identify patients with cancer who may benefit from primary thromboprophylaxis.
2. Compare data for use of direct oral anticoagulants (DOACs) versus low-molecular weight heparin (LMWH) in the treatment of cancer-associated thrombosis (CAT).
3. Select the most appropriate anticoagulant for treatment of CAT given patient-specific characteristics.
4. Discuss duration of treatment for CAT.

UAN#: 0465-0000-24-089-H01-P

Authors:  Adam J. DiPippo, PharmD, BCOP

Caitlin R. Rausch, PharmD, BCOP

Shilpa Paul, PharmD, BCOP

Learning Objectives:

1. Describe the natural history and past treatment paradigm of acute leukemias in elderly patients
2. Summarize current advances and novel agents used in the treatment of elderly patients with acute leukemias
3. Apply evidence-based principles to clinical scenarios of elderly patients with acute leukemia, including dose modifications and supportive care management
4. Evaluate the clinical evidence and place in therapy of novel agents for elderly patients with ALL and AML including inotuzumab, blinatumomab, BCR::ABL1 tyrosine kinase inhibitors, venetoclax, IDH and FLT3 inhibitors
5. Design a comprehensive treatment regimen for elderly patients with acute leukemia utilizing patient-specific factors and goals of therapy

UAN#: 0465-0000-24-090-H01-P

Author: Erin Kelley, PharmD BCOP

Learning Objectives:

1. Describe recent trials examining the addition of immunotherapy to chemotherapy in early stage NSCLC
2. Select an appropriate therapy regimen for patients with early stage NSCLC
3. Summarize data on approved adjuvant targeted therapies in early stage NSCLC
4. Outline the updated published overall survival data for therapies in NSCLC
5. Identify patients appropriate for new targeted therapies in late stage NSCLC
6. Differentiate adverse effects associated with targeted NSCLC treatments

UAN#: 0465-0000-24-091-H01-P

Author: Christine Barrett, PharmD, BCOP

Learning Objectives:

1. Define the current role of PARP inhibitors in ovarian cancer based on long-term follow-up data and approved indications
2. Describe the role of mirvetuximab soravtansine-gynx in ovarian cancer, including a review of its mechanism of action, dosing, and side effects, as well as efficacy and safety data
3. Summarize ongoing clinical trials and future areas of interest in ovarian cancer
4. Describe the role of immunotherapy in advanced or recurrent endometrial cancer
5. Discuss the role of molecular testing and current evidence for risk stratification in endometrial cancer
6. Identify notable ongoing studies in the treatment of endometrial cancer